ODDITY Tech (ODD) has an average rating of hold and mean price target of $12.72, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MDT posted Q4 FY 26 (Apr.) revenue of $9.8B (+9.9% reported, +6.6% organic), beating consensus by $194M, while non-GAAP EPS of $1.55 beat the consensus view by $0.01 but declined 4.3% Y/Y. The Cardiovascular Portfolio delivered solid 13.8% Y/Y growth to $3.8B in Q4, led by Cardiac Ablation Solutions sales surging 78% globally, reflecting rapid adoption of pulsed field ablation technologies. However, FY 27 guidance disappointed with non-GAAP EPS of $5.90-$6.00 below consensus at the midpoint of $5.95. Regulatory milestones including FDA submissions for Hugo robotic surgery system and CathWorks acquisition completion could advance growth, in our view. We think the active M&A strategy with Scientia Vascular and SPR Therapeutics acquisitions could complement organic innovation and boost revenues. While MDT could continue solid top-line performance with its robust pipeline and market positions, we believe margin pressures from rising costs, supply chain challenges, and tariffs could negatively impact profitability.
Panmure Liberum on Tuesday lowered renewable assets investor Bluefield Solar Income Fund's (BSIF.L) rating to hold from buy, while raising its price target to 0.93 pound sterling from 0.795 pound.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)